Cargando…

The true historical origin of convalescent plasma therapy

Detalles Bibliográficos
Autores principales:	Marson, Piero, Cozza, Andrea, De Silvestro, Giustina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289739/ https://www.ncbi.nlm.nih.gov/pubmed/32565057 http://dx.doi.org/10.1016/j.transci.2020.102847

Ejemplares similares

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

The cunning bookcase of Alexander Knips Macoppe
por: Marson, Piero, et al.
Publicado: (2022)

Convalescent plasma therapy for persistent hepatitis E virus infection
por: Ankcorn, Michael, et al.
Publicado: (2019)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies
por: De Silvestro, Giustina, et al.
Publicado: (2021)

Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry
por: De Silvestro, Giustina, et al.
Publicado: (2022)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
por: Xi, Yongzhi
Publicado: (2020)

Acute pancreatitis due to severe hypertriglyceridemia in the COVID-19 era: The role of therapeutic plasma exchange
por: Pavanello, Francesca, et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining
por: Deokar, Kunal, et al.
Publicado: (2020)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?
por: Stevens, Michael P., et al.
Publicado: (2020)

Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
por: Basic-Jukic, Nikolina
Publicado: (2020)

Clinical efficacy of convalescent plasma therapy on treating COVID‐19 patients: Evidence from matched study and a meta‐analysis
por: Jiang, Weijun, et al.
Publicado: (2020)

Whole blood derived covid convalescent plasma: An economical option among developing countries
por: Ravula, Ushasree, et al.
Publicado: (2021)

Whole blood derived covid convalescent plasma: A practical experience from India
por: Mandal, Abhijit, et al.
Publicado: (2021)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

What are the hurdles in the pathway of COVID-19 convalescent plasma collection in low-income nations?
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Convalescent plasma: A possible treatment of COVID-19 in India
por: Teixeira da Silva, Jaime A.
Publicado: (2020)

Convalescence, Historical and Practical
Publicado: (1928)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

Convalescent plasma for covid19 – How long should a donor be excluded from donation?
por: Kutner, Jose M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2qstckr8op12ovom5o6j0rt1ob